Abstract
Tissue engineering ex vivo and direct cellular application with bioscaffolds in vivo has allowed surgeons to restore and establish function throughout the human body. The evidence for regenerative surgery is growing, and consequently there is a need for the development of more advanced regenerative surgery facilities. Regenerative medicine in the surgical field is changing rapidly and this must be reflected in the design of any future operating suite. The theater environment needs to be highly adaptable to account for future significant advances within the field. Development of purpose built, combined operating suites and tissue-engineering laboratories will provide the facility for modern surgeons to treat patients with organ deficits, using bespoke, regenerated constructs without the need for immunosuppression.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 785-791 |
| Number of pages | 7 |
| Journal | Regenerative Medicine |
| Volume | 9 |
| Issue number | 6 |
| DOIs | |
| State | Published - Nov 1 2014 |
| Externally published | Yes |
Fingerprint
Keywords
- biotechnology
- operating room
- operating theater
- reconstruction
- regeneration
- regenerative medicine
- scaffold
- stem cells
- surgery
- tissue engineering
ASJC Scopus subject areas
- Biomedical Engineering
- Embryology
Cite this
Operating RegenMed : Development of better in-theater strategies for handling tissue-engineered organs and tissues. / Fishman, Jonathan M.; Wormald, Justin C R; Lowdell, Mark W.; De Coppi, Paolo; Birchall, Martin A.
In: Regenerative Medicine, Vol. 9, No. 6, 01.11.2014, p. 785-791.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Operating RegenMed
T2 - Development of better in-theater strategies for handling tissue-engineered organs and tissues
AU - Fishman, Jonathan M.
AU - Wormald, Justin C R
AU - Lowdell, Mark W.
AU - De Coppi, Paolo
AU - Birchall, Martin A.
PY - 2014/11/1
Y1 - 2014/11/1
N2 - Tissue engineering ex vivo and direct cellular application with bioscaffolds in vivo has allowed surgeons to restore and establish function throughout the human body. The evidence for regenerative surgery is growing, and consequently there is a need for the development of more advanced regenerative surgery facilities. Regenerative medicine in the surgical field is changing rapidly and this must be reflected in the design of any future operating suite. The theater environment needs to be highly adaptable to account for future significant advances within the field. Development of purpose built, combined operating suites and tissue-engineering laboratories will provide the facility for modern surgeons to treat patients with organ deficits, using bespoke, regenerated constructs without the need for immunosuppression.
AB - Tissue engineering ex vivo and direct cellular application with bioscaffolds in vivo has allowed surgeons to restore and establish function throughout the human body. The evidence for regenerative surgery is growing, and consequently there is a need for the development of more advanced regenerative surgery facilities. Regenerative medicine in the surgical field is changing rapidly and this must be reflected in the design of any future operating suite. The theater environment needs to be highly adaptable to account for future significant advances within the field. Development of purpose built, combined operating suites and tissue-engineering laboratories will provide the facility for modern surgeons to treat patients with organ deficits, using bespoke, regenerated constructs without the need for immunosuppression.
KW - biotechnology
KW - operating room
KW - operating theater
KW - reconstruction
KW - regeneration
KW - regenerative medicine
KW - scaffold
KW - stem cells
KW - surgery
KW - tissue engineering
UR - http://www.scopus.com/inward/record.url?scp=84913610543&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84913610543&partnerID=8YFLogxK
U2 - 10.2217/rme.14.46
DO - 10.2217/rme.14.46
M3 - Article
VL - 9
SP - 785
EP - 791
JO - Regenerative Medicine
JF - Regenerative Medicine
SN - 1746-0751
IS - 6
ER -